Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ODE II director

This article was originally published in The Tan Sheet

Executive Summary

FDA names Curtis Rosebraugh director of the Office of Drug Evaluation II after nine months as acting director of the office in the Center for Drug Evaluation and Research. He will oversee the divisions of Anesthesia, Analgesia and Rheumatology Products, Metabolism and Endocrinology Products and Pulmonary and Allergy Products. Rosebraugh from 2003-2005 served as deputy director of the Office of Nonprescription Products, with responsibilities including acting director of ONP's Division of Nonprescription Clinical Evaluation (1"The Tan Sheet" Feb. 10, 2003, In Brief). In 2005 he was named deputy director of the ODE II and became acting director in September 2007...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS101672

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel